The Growth Control Program is composed of 38 investigators (34 Full and 4 Associate members) from 15 Departments with a common interest in understanding the cellular and molecular mechanisms by which eukaryotic cells regulate survival proliferation, and/or division. Moreover, members of this Program are committed to integrating basic research with an understanding of malignant transformation and the identification of targets for cancer therapeutics. The overall goal of the Program is to actively promote research collaborations amongst its members and facilitate the application of a wide range of cutting-edge research tools and approaches to better understand basic regulatory mechanisms that suppress malignant transformation in human cells. The Program has the following Specific Aims: 1) To study transcriptional and epigenetic machineries that regulate cell proliferation and differentiation;2) To elucidate intracellular cell signaling networks regulating cell survival and growth;3) To determine how cells control their division and checkpoints;4) To understand the mechanisms of action of oncogenes and tumor suppressors;and 5) To translate the knowledge generated from basic studies into tools to fight cancer. Wei Dai and Michele Pagano are the Co-Leaders for this Program. Total funding increased from $16,079,153 to $16,483,886 since the last competitive application. Membership has decreased from 45 to 38. Publications for the period total 477, of which 7.5% are intra-programmatic, 19.3% are inter-programmatic, and 2.7% are both intra- and interprogrammatic collaborations.
Cancer is a collection of diseases characterized by uncontrolled cell growth. Deregulated cellular and molecular processes that govern cell survival, division, and/or death play key roles in the development of cancer. The Program functions to promote research collaborations among its members to better understand basic mechanisms that curb cancer development.
|Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247|
|Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190|
|Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226|
|Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242|
|Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:|
|Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:|
|Marié, Isabelle J; Chang, Hao-Ming; Levy, David E (2018) HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med 215:3194-3212|
|Gupta, Ankit; Xu, Jing; Lee, Shirley et al. (2018) Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol 14:895-900|
|Lee, Hyun-Wook; Park, Sung-Hyun; Weng, Mao-Wen et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc Natl Acad Sci U S A 115:E1560-E1569|
|Evensen, Nikki A; Madhusoodhan, P Pallavi; Meyer, Julia et al. (2018) MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103:830-839|
Showing the most recent 10 out of 1170 publications